Begrundelsen for artikel 30- indbringelsen af sagen vedrørende Roaccutan var, at Roaccutan som følge af divergerende nationale afgørelser ikke har samme produktresumé i alle medlemsstater.
The rationale for the article 30 referral of Roaccutane was due to the fact that Roaccutane does not have the same SPC across all Member States due to divergent national decisions.